Affective mediators of the association between pleasant events and global sleep quality in community-dwelling adults

This study explored the association of engagement in pleasant events and global sleep quality, as well as examined the intermediary roles of positive affect and depressive symptoms in this association. Data were derived from the Midlife in the United States-II study. The sample consisted of 1054 community-dwelling adults. Participants completed the Pittsburgh Sleep Quality Index and indicated the frequency and enjoyableness of experiences on a positive events scale. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale. Positive affect was measured using the Mood and Symptoms Questionnaire. Regression analyses indicated more frequent engagement in pleasant events was associated with better global sleep quality. Depressive symptoms, but not positive affect, partially mediated the association between pleasant events and global sleep quality. The findings suggest that behavioral engagement in pleasant events may be related to global sleep quality via depressive symptoms, but not positive affect. These findings highlight the potential for engagement in pleasant activities to influence both mood and sleep.     

Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge

An anti-poxvirus vaccine based on replicon particles of Venezuelan equine encephalitis virus (VRP) is being developed. The cowpox virus genes encoding structural proteins corresponding to vaccinia virus proteins A33, B5, and A27 were each expressed from VRP. High serum IgG titers against these proteins were generated in BALB/c mice vaccinated with each of these VRP. VRP induced both IgG1 and IgG2a with a strong predominance of IgG2a production. The response is long-lasting, as evidenced by the retention of high anti-B5 serum IgG titers through at least 50 weeks after priming immunization. Mice vaccinated with B5-, A33- or A27-VRP individually or together survived intranasal challenge with cowpox virus, with the multivalent vaccine formulation providing more effective protection from weight loss and clinical signs of illness than the monovalent vaccines. These results demonstrate that VRP may provide an effective alternative to vaccinia virus vaccines against poxvirus infection.     

Beliefs regarding the consequences of obesity and ideal weight: an instrument development study

OBJECTIVE: To address the current lack of psychometrically sound measures of beliefs regarding the consequences of obesity and ideal weight that has limited research to-date. METHODS: In phase one, interviews with 22 healthy-weight, overweight and obese individuals were conducted, subjected to theme analysis and used to develop 40 items. In phase two, unsound items were removed following item and principal components analyses of data from a community sample of 188 participants. In phase three, the items selected in phase two were administered to a second workforce population (n=302) to ensure their excellent psychometric properties were stable. In phase four, data were collected from 104 obese clinic attendees to establish the subscales' construct validity. RESULTS: The resultant Obesity Beliefs Scale (OBS) is comprised of three short, reliable, unidimensional and valid subscales written in language suitable for individuals aged 12 years and above. CONCLUSION: The OBS is a psychometrically sound measure of beliefs regarding the consequences obesity and ideal weight. PRACTICE IMPLICATIONS: The OBS has the potential to play a key role in prospective research designed to fully determine the role of beliefs in weight control behaviour. It can also be used to target and assess health education interventions.     

A multiple case study of data use practice in eight early childhood centres in the Republic of Trinidad and Tobago

ABSTRACT

Formative assessment and effective use of data to support student learning are key components of practice in early childhood (EC) centres. Although Trinidad and Tobago has developed an impressive EC care system, to decrease the achievement gap which international studies have shown to be significant in core subjects, educational planners must ensure that teachers make better use of data. This study explored data use practice in eight geographically diverse EC centres. Using maximum variation sampling, data were collected from focus group teacher interviews, observation and document analysis. Thematic analysis and constant comparison were used to identify differences across sites and to generate theory on practice. The theory identifies data use practice in an emerging Caribbean society lacking a robust data culture and with limited professional development opportunities. Implications for policy, professional sdevelopment and system reform of the EC sector in Trinidad and Tobago are included.     

Die Prävalenz der COPD in Österreich – die erwartete Entwicklung bis 2020

BACKGROUND: In 2020 Chronic obstructive pulmonary disease (COPD) will be the third leading cause of death world-wide causing considerable health costs. Epidemiological data to estimate the future development of COPD in Austria were not available so far. METHODS: In the context of the international Burden of Obstructive Lung Disease (BOLD) study, a random sample of the population of Salzburg was surveyed to determine the prevalence of COPD. The definition of COPD followed the GOLD classification. A prior physician's diagnosis of COPD, emphysema or chronic bronchitis was evaluated by questionnaire. The age- and sex-specific prevalence of COPD was extrapolated using demographic data of the Austrian population for the years 2005, 2010, 2015 and 2020. Undiagnosed COPD was considered present, whenever irreversible airways obstruction was measured (FEV1/FVC < 0.7), but a doctor's diagnosis of COPD, emphysema or chronic bronchitis has not been made. RESULTS: For 2005 1.047.150 Austrians aged 40 years and older were estimated in GOLD stage I-IV. 431.080 persons over 40 years were affected by COPD in GOLD stage II-IV needing therapy. The percentage of undiagnosed COPD was 88,5%. For the years 2010, 2015 and 2020 GOLD stage I-IV COPD was projected to rise by 7,8%, 16.1% and 24%, respectively. CONCLUSION: Measures to prevent COPD are absolutely necessary to forestall the projected burden of this disease in Austria.     

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

The effect of the potent and selective poly(ADP-ribose) (PAR) polymerase-1 [and PAR polymerase-2] inhibitor CEP-8983 on the ability to sensitize chemoresistant glioblastoma (RG2), rhabdomyosarcoma (RH18), neuroblastoma (NB1691), and colon carcinoma (HT29) tumor cells to temozolomide- and camptothecin-induced cytotoxicity, DNA damage, and G(2)-M arrest and on the potentiation of chemotherapy-induced myelotoxicity was evaluated using in vitro assays. In addition, the effect of the prodrug CEP-9722 in combination with temozolomide and/or irinotecan on PAR accumulation and tumor growth was also determined using glioblastoma and/or colon carcinoma xenografts relative to chemotherapy alone. CEP-8983 sensitized carcinoma cells to the growth-inhibitory effects of temozolomide and/or SN38 increased the fraction of and/or lengthened duration of time tumor cells accumulated in chemotherapy-induced G(2)-M arrest and sensitized tumor cells to chemotherapy-induced DNA damage and apoptosis. A granulocyte-macrophage colony-forming unit colony formation assay showed that coincubation of CEP-8983 with temozolomide or topotecan did not potentiate chemotherapy-associated myelotoxicity. CEP-9722 (136 mg/kg) administered with temozolomide (68 mg/kg for 5 days) or irinotecan (10 mg/kg for 5 days) inhibited significantly the growth of RG2 tumors (60%) or HT29 tumors (80%) compared with temozolomide or irinotecan monotherapy, respectively. In addition, CEP-9722 showed "stand alone" antitumor efficacy in these preclinical xenografts. In vivo biochemical efficacy studies showed that CEP-9722 attenuated PAR accumulation in glioma xenografts in a dose- and time-related manner. These data indicate that CEP-8983 and its prodrug are effective chemosensitizing agents when administered in combination with select chemotherapeutic agents against chemoresistant tumors.